Skip to main content
. 2013 Jul 10;13:340. doi: 10.1186/1471-2407-13-340

Table 1.

Characteristics of the study population

 
All cancers (n=6675)
Lung (n=2367)
Breast (n=1739)
CRC (n=1860)
Liver (n=709)
Variables No. of patients (%) No. of patients (%) No. of patients (%) No. of patients (%) No. of patients (%)
Age (Mean ± SD)
62.4 ± 11.3
65.5 ± 11.3
56.3 ± 13.3
64.7 ± 13.8
61.0 ± 11.3
Gender
Female
4081(61.14)
1232(52.05)
1739(100)
949(51.02)
161(22.71)
Male
2594(38.86)
1135(47.95)
 
911(48.98)
548(77.29)
Ethnicity
Caucasian
4758(71.28)
1780(75.2)
1123(64.58)
1403(75.43)
452(63.75)
Black
1445(21.65)
468(19.77)
491(28.23)
359(19.3)
127(17.91)
Others
472(7.07)
119(5.03)
125(7.19)
98(5.28)
130(18.33)
Tumor stages
Stage 0
325(4.87)
1(0.04)
264(15.18)
60(3.23)
 
Stage 1
1764(26.43)
533(22.52)
605(34.79)
419(22.53)
207(29.2)
Stage 2
1272(19.06)
158(6.68)
527(30.3)
454(24.41)
133(18.76)
Stage 3
1207(18.08)
465(19.65)
164(9.43)
418(22.47)
160(22.57)
Stage 4
1659(24.85)
1042(44.02)
119(6.84)
385(20.7)
113(15.94)
Unknown
448(6.71)
168(7.09)
60(3.45)
124(6.67)
96(13.54)
Tumor grades
Well
515(7.71)
124(5.24)
155(8.91)
172(9.25)
64(9.03)
Moderately
2260(33.86)
427(18.04)
575(33.06)
1138(61.18)
120(16.93)
Poorly
1514(22.68)
630(26.62)
605(34.79)
250(13.44)
29(4.09)
Not determined
2386(35.75)
1186(50.1)
404(23.23)
300(16.13)
496(69.96)
Chemotherapy
No
2258(33.83)
258(10.9)
989(56.87)
918(49.35)
93(13.12)
Yes
2865(42.92)
948(40.05)
705(40.54)
840(45.16)
372(52.47)
Unknown
1552(23.25)
1161(49.05)
45(2.59)
102(5.48)
244(34.41)
Radiation
No
2933(43.94)
208(8.79)
1097(63.08)
1492(80.22)
136(19.18)
Yes
1929(28.9)
970(40.98)
582(33.47)
335(18.01)
42(5.92)
Unknown
1813(27.16)
1189(50.23)
60(3.45)
33(1.77)
531(74.89)
Surgery
No
1134(16.99)
615(25.98)
95(5.46)
210(11.29)
214(30.18)
Yes
4832(72.39)
1200(50.7)
1644(94.54)
1650(88.71)
338(47.67)
Unknown
709(10.62)
552(23.32)
 
 
157(22.14)
Vital status
Alive
3133(46.94)
572(24.17)
1374(79.01)
986(53.01)
201(28.35)
Dead 3542(53.06) 1795(75.83) 365(20.99) 874(46.99) 508(71.65)